A recent breakthrough study from Duke Health, published on August 10, 2026, provides much-needed clarity on how lecanemab performs when administered outside the strict confines of a trial. For families and patients navigating this new landscape, the findings offer both reassurance and a roadmap for safety.

For years, we have known that people with early-stage Alzheimer’s often struggle to get a good night's rest. For a long time, scientists thought this was simply because of "plaques"—sticky protein buildups called amyloid—clogging up the brain. However, new research from the University of Kentucky suggests the problem isn't just the plaques

This isn't about AI replacing your doctor; it’s about giving your doctor a massive head start. Catching Alzheimer's risk seven years early opens up a golden window for aggressive lifestyle interventions, personalized therapies, and early-stage clinical trials.